An update on: molecular genetics of high-risk chronic lymphocytic leukemia

Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Mattia Schipani(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Silvia Rasi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Chiara Favini(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Clara Deambrogi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Ahad Ahmed Kodipad(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Andrea Patriarca(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Expert Review of Hematology
November 27, 2019
10.1080/17474086.2020.1697225
Cited by 10

Related Papers

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
|Blood|2015|216
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
|Journal of Clinical Oncology|2014|210